• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kamada (TASE:KMDA) Stock Quietly Ignores A Stronger Profit Run Rate

    Simply Wall St·08/13/2026 17:31:06
    Listen to the news

    The market has treated Kamada like just another small biotech, with the stock roughly flat over the past week and slightly weaker over three months, even as the latest report lands. That calm reaction sits beside a quarter built around one clear story. Q2 2026 revenue reached US$54.9m and net income came in at US$9.3m, which marks the strongest profit trend in the recent history provided.

    This is the sentiment gap investors now need to judge. Is a quiet share price move the right response to visibly improving earnings power, or is the market underpricing a cleaner, higher quality profit run rate?

    Impressed by Kamada's cleaner profit run rate but want more ideas with similar earnings quality and solid balance sheets? Check out the list of solid balance sheet and fundamentals stocks (429 results)

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: US$54.9m vs. US$44.8m (up 22.7%)
    • Net Income, Q2 2026 vs. Q2 2025: US$9.3m vs. US$7.4m (up 25.6%)
    • Basic EPS, Q2 2026 vs. Q2 2025: US$0.16 vs. US$0.13 (up 23.1%)
    • Net Profit Margin, Trailing 12 Months vs. Prior Year: 11.6% vs. 11.2% (higher margin level)

    Prefer clean charts instead of another wall of financial tables and earnings headlines? See Kamada's full financial picture, including a visual view of its valuation, in the company report for Kamada.

    TASE:KMDA Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    TASE:KMDA Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Kamada earnings momentum and balance sheet strength

    Kamada’s latest quarter backs up a cautiously bullish view. Revenue reached US$54.9m in Q2 2026 with double digit growth versus Q2 2025, while net income moved to US$9.3m. H1 2026 revenue of US$100.2m and adjusted EBITDA of US$25.7m, with a 26% margin, indicate a business converting sales into cash. Operating cash flow improved to about US$17.8m, and cash and short term investments stand at US$70.1m even after a US$14.4m dividend. Together, these figures support the idea of a diversified, commercially focused platform.

    Kamada risk factors and concentration still matter

    The bear case for Kamada is not dismissed by one strong quarter. Growth leans heavily on a handful of plasma products such as KEDRAB and GLASSIA and on partners like Kedrion and Takeda. Management flagged gross margin variability due to product mix, which can pressure profitability even when revenue rises. There is execution risk around scaling three U.S. plasma collection centers and delivering on the US$50m plasma supply contract. A coming CFO change also adds a layer of uncertainty that investors are likely to watch closely.

    With Kamada committing cash to dividends and plasma expansion while investors focus on earnings, you need to verify how much balance sheet flexibility is left. Check the real liquidity and debt picture in our financial health analysis of Kamada stock.

    Stay Ahead With Kamada Insights

    If Kamada’s recent earnings strength and cash position have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on the most important portfolio updates. For longer term conviction, lean on the Community to see how other investors are thinking about Kamada and stocks with similar traits. This way you can spot hidden catalysts and risks earlier and stay ahead of the wider market.

    Seeking Alternatives Beyond Kamada?

    Fresh opportunities often move from quiet to breakout faster than many expect. Spot stocks building real momentum while information is still under the radar for now, and consider getting in early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.